Smithkline Beecham Corporation

Glaxosmithkline LLC

Glaxo Wellcome Inc.

David Norman Deaton

Frank Navas, Iii

Paul Kenneth Spearing

John George Catalano

Marc W Andersen

Aaron Bayne Miller

Richard Dama Caldwell

Robert Blount McFadyen

Michael Luzzio

Francis Xavier Tavares

Susan Mary Daluge

Leroy B Townsend

John Charles Drach

Brian Edward Marron

Stanley Dawes Chamberlain

Timothy Mark Willson

Istvan Kaldor

Robert Anthony Mook

Scott Howard Dickerson

David Harold Drewry

David John Cowan

Barry George Shearer

Curt Dale Haffner

Jon Loren Collins

Grady Evan Boswell

Matthew J Sharp

Darryl Lynn McDougald

Amarjit Sab Randhawa

David Edward Uehling

John Albert Ray

Robert Carl Andrews

Steven Michael Reister

Brad Richard Henke

Marcus Brackeen

George Andrew Freeman

David Gene Barrett

Michael Howard Rabinowitz

Michael David Gaul

Frank Leslie Boyd, Jr

John Mark O'Callaghan

Vicente Samano

Jeffrey Edmond Cobb

Jonathan York Bass, Iii

Justin Caravella

Robert Blout McFayden

Greg Alan Erickson

Jonathan York Iii Bass

Frank Iii Navas

Robert Blount Mcfadyen

The present invention provides novel substituted isoxazole compounds, pharmaceutical compositions, therapeutic uses and processes for preparing the same.

Farnesoid X receptor agonists

Heterocycle substituted ketoamide derivatives of Formula (I), wherein the substitutes A, D, A and R are defined as in claim in, which are useful as cathepsin K inhibitors are described herein. The described invention also includes methods of making such heterocycle substituted ketoamide derivatives as well as method of using the same in the manufacture of medicaments for the treatment of disorders, including osteoporosis, associated with an imbalance between bone resorption and formation which can ultimately lead to fracture.

Derivatives of 1-(oxoaminoacetyl) pentylcarbamate as cathepsin K inhibitors for the treatment of bone loss

The present invention includes ketone derivatives (I) and (II), which are useful as cathepsin K inhibitors. The described invention also includes methods of making such ketone derivatives as well as methods of using the same in the treatment of disorders, including osteoporosis 

Propylcarbamate derivatives as inhibitors of serine and cysteine proteases

Cycloalkyl ketoamide derivatives, which are useful as cathepsin K inhibitors are described herein. The described invention also includes methods of making such cycloalkyl ketoamide derivatives as well as methods of using the same in the treatment of disorders, including osteoporosis, associated with enhanced bone turnover which can ultimately lead to fracture.

Cycloalkyl ketoamides derivatives useful as cathepsin K inhibitors

The present invention relates to novel compounds, their use for inhibiting serine proteases, such as dipeptidyl peptidases, such as dipeptidyl peptidase IV (DPP-IV) and to methods for their production and their therapeutic utility 

Pyrrolidines as dipeptidyl peptidase inhibitors

The present invention disclosed compounds of Formula I. The present invention also discloses beta-3 agonists of formula I and methods for treating beta-3 mediated diseases and condition using the compounds of formula I, in particular methods for treating diabetes or obesity.

Phenethanolamine derivatives, compositions, and their use as agonists at atypical beta-adrenoreceptors

Benzimidazole derivatives useful for treating or preventing viral infections such as those caused by herpes viruses or in the treatment of restenosis following surgical techniques. Methods of preparing these benzimidazole derivatives and pharmaceutical compositions containing them are described.

Benzimidazole derivatives

A compound having formula (I), wherein A is selected from the group consisting of: (i) phenyl, wherein said phenyl is optionally substituted by one or more halogen atoms, C,alkyl, C,alkoxy, C,fluoroalkoxy, nitrile, or &mdash;NR,R,where R,and R,are independently hydrogen or C,alkyl; (ii) a 5- or 6-membered hetrocyclic group containing at least one heteroatom selected from oxygen, nitrogen and sulfur; and (iii) a fused bicyclic ring (a), wherein ring C represents a heterocyclic group as defined in point (ii) above, which bicyclic ring is attached to group B via a ring atom of ring C; B is selected from the group consisting of: (iv) C,alkylene; (v) &mdash;MC,alkylene or C,alkyleneMC,alkylene, wherein M is O, S, or &mdash;NR,wherein R,represents hydrogen or C,alkyl; (vi) a 5- or 6-membered heterocyclic group containing at least one nitrogen heteroatom and optionally at least one further heteroatom selected from oxygen, nitrogen and sulfur and optionally substituted by C,alkyl; and (vii) Het-C,alkylene, wherein Het represents a heterocyclic group as defined in point (vi) above; Alk represents C,alkylene; R,represents hydrogen or C,alkyl; Z is selected from the group consisting of: (viii) &mdash;(C,alkylene) phenyl, which phenyl is optionally substituted by one or more halogen atoms; and (ix) &mdash;NR,R,, wherein R,represents hydrogen or C,alkyl, and R,represents &mdash;Y&mdash;(C&boxH;O)&mdash;T&mdash;R,, or &mdash;Y&mdash;(CH(OH))&mdash;T&mdash;R,.

Substituted 4-hydroxy-phenylalcanoic acid derivatives with agonist activity to PPAR-gamma

A family of compounds having the general structural formula

Formamides as therapeutic agents

Growing community of inventors

Durham, NC, United States of America

David Norman Deaton